Ravulizumab for adults with generalized myasthenia gravis: a plain language summary of three studies

What is this summary about? Generalized myasthenia gravis (often shortened to gMG) is a rare health condition that causes muscular weakness. This summary gives an overview of three published articles that report the results of research studies of a medicine called ravulizumab, a treatment approv...

Full description

Saved in:
Bibliographic Details
Main Authors: Florencia Aguirre, Renata Andrade
Format: Article
Language:English
Published: Becaris Publishing Limited 2024-10-01
Series:Journal of Comparative Effectiveness Research
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850198650626506752
author Florencia Aguirre
Renata Andrade
author_facet Florencia Aguirre
Renata Andrade
author_sort Florencia Aguirre
collection DOAJ
description What is this summary about? Generalized myasthenia gravis (often shortened to gMG) is a rare health condition that causes muscular weakness. This summary gives an overview of three published articles that report the results of research studies of a medicine called ravulizumab, a treatment approved for adults with gMG. These studies are: • The CHAMPION MG study. • The CHAMPION MG extension study. • A study of how the body processes and responds to ravulizumab (known as pharmacokinetics and pharmacodynamics). These studies looked at how effective and safe ravulizumab is for people with gMG.
format Article
id doaj-art-67bb5efd245f4d099f051f4d0371a063
institution OA Journals
issn 2042-6313
language English
publishDate 2024-10-01
publisher Becaris Publishing Limited
record_format Article
series Journal of Comparative Effectiveness Research
spelling doaj-art-67bb5efd245f4d099f051f4d0371a0632025-08-20T02:12:49ZengBecaris Publishing LimitedJournal of Comparative Effectiveness Research2042-63132024-10-01131110.57264/cer-2024-0109Ravulizumab for adults with generalized myasthenia gravis: a plain language summary of three studiesFlorencia Aguirre0Renata Andrade1Neurophysiology and Neuromuscular Diseases Section, Hospital Gral de agudos JM Ramos Mejía, Buenos Aires, ArgentinaDivision of Rare Diseases, Real Hospital Português, Recife, BrazilWhat is this summary about? Generalized myasthenia gravis (often shortened to gMG) is a rare health condition that causes muscular weakness. This summary gives an overview of three published articles that report the results of research studies of a medicine called ravulizumab, a treatment approved for adults with gMG. These studies are: • The CHAMPION MG study. • The CHAMPION MG extension study. • A study of how the body processes and responds to ravulizumab (known as pharmacokinetics and pharmacodynamics). These studies looked at how effective and safe ravulizumab is for people with gMG.generalized myasthenia gravisgmgmuscular weaknessplain language summaryravulizumab
spellingShingle Florencia Aguirre
Renata Andrade
Ravulizumab for adults with generalized myasthenia gravis: a plain language summary of three studies
Journal of Comparative Effectiveness Research
generalized myasthenia gravis
gmg
muscular weakness
plain language summary
ravulizumab
title Ravulizumab for adults with generalized myasthenia gravis: a plain language summary of three studies
title_full Ravulizumab for adults with generalized myasthenia gravis: a plain language summary of three studies
title_fullStr Ravulizumab for adults with generalized myasthenia gravis: a plain language summary of three studies
title_full_unstemmed Ravulizumab for adults with generalized myasthenia gravis: a plain language summary of three studies
title_short Ravulizumab for adults with generalized myasthenia gravis: a plain language summary of three studies
title_sort ravulizumab for adults with generalized myasthenia gravis a plain language summary of three studies
topic generalized myasthenia gravis
gmg
muscular weakness
plain language summary
ravulizumab
work_keys_str_mv AT florenciaaguirre ravulizumabforadultswithgeneralizedmyastheniagravisaplainlanguagesummaryofthreestudies
AT renataandrade ravulizumabforadultswithgeneralizedmyastheniagravisaplainlanguagesummaryofthreestudies